Home › Trials › NCT07205510
Clinical trial Recruiting at 1 site Observational Ages 18 and up

SMILE: Tracking muscle loss, metabolic health, and aging over time

Official title: Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)

Run by RenJi Hospital · NCT07205510 · Data updated 2026-11-12

This project will follow adults to see if combining clinical data, imaging, and blood/tissue samples can detect and track muscle loss and metabolic changes linked to aging.

More Aging trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment10000 (estimated)
SponsorRenJi Hospital
Academic / other
Locations1 site (Shanghai)
StatusRecruiting
StartedDecember 1, 2020
Main results expectedDecember 31, 2040
Study endsDecember 31, 2040
Registry record updatedOctober 3, 2025
Trial IDNCT07205510 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older who can give informed consent and participate in clinic visits and assessments are the intended participants.

Probably not a fit

People who cannot consent, are unconscious, have severe mental illness preventing communication, or have conditions that would confound assessments are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

SMILE is an ambispective cohort that combines retrospective records with prospective follow-up to map the pathological axis linking sarcopenia, metabolic disorders, and aging. The platform collects multimodal data including demographics, lifestyle factors, clinical phenotypes, laboratory tests, medical imaging, and biospecimens. Researchers will use these data to identify early signs of muscle aging, patterns connecting metabolic disease and sarcopenia, and predictors of adverse outcomes such as disability and mortality. The work is based at RenJi Hospital, Shanghai Jiaotong University, with adults aged 18 and over eligible to participate.

Why it matters

Potential benefit: If successful, the platform could enable earlier detection of muscle and metabolic decline and guide interventions to reduce falls, disability, and premature death.

How similar studies have gone: Prior cohort studies have linked sarcopenia with metabolic and cardiovascular risk, but large ambispective, multimodal platforms like SMILE are relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Adults aged 18 and over

Exclusion Criteria:

1. Does not cooperate in signing the informed consent form;
2. Does not possess legal capacity;
3. In a state of loss of consciousness;
4. Suffering from severe mental illness, unable to communicate normally;
5. The researcher believes that the subject has a disease that affects the assessment of results and is unsuitable for inclusion.

Where it's running

  • Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
    Shanghai, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Sarcopenia 155Metabolic Diseases 33All-cause Mortality 6Aging 2413Cardiometabolic Diseases 35RenJi Hospital 95
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.